Virtus ETF Advisers LLC Has $73,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Virtus ETF Advisers LLC cut its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 40.2% during the 4th quarter, Holdings Channel reports. The fund owned 2,834 shares of the company’s stock after selling 1,904 shares during the period. Virtus ETF Advisers LLC’s holdings in NewAmsterdam Pharma were worth $73,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. National Bank of Canada FI acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. bought a new position in NewAmsterdam Pharma in the fourth quarter worth approximately $80,000. Barclays PLC grew its stake in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $154,000. Finally, HB Wealth Management LLC acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter worth approximately $224,000. 89.89% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at approximately $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James N. Topper bought 4,005 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was bought at an average price of $21.02 per share, for a total transaction of $84,185.10. Following the completion of the purchase, the director now owns 3,012,434 shares of the company’s stock, valued at approximately $63,321,362.68. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 19.50% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the subject of several research reports. HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Needham & Company LLC reissued a “buy” rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, April 8th. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank lifted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Finally, UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research note on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $43.33.

NewAmsterdam Pharma Stock Performance

NewAmsterdam Pharma stock opened at $17.83 on Tuesday. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The firm’s 50-day simple moving average is $19.58 and its 200 day simple moving average is $21.24. The stock has a market cap of $1.96 billion, a PE ratio of -6.86 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $3.30 million. As a group, analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.